Scholar Rock stocks skyrocket after SMA drug scores at Phase III

Oct 8, 2024 · Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. The Phase III SAPPHIRE trial (NCT05156320) …

CouponFollow Extension

320%
OFF

Scholar Rock (SRRK) Shares Soar Over 320% On SMA Topline …

2 weeks from now

New York, October 07, 2024 - PRISM MarketView - The late-stage biopharmaceutical company Scholar Rock who focuses on treatments for spinal muscular atrophy (SMA), cardiometabolic …

prismmarketview.com

315%
OFF

Scholar Rock's Stock Soars More Than 315% On Positive Trial Of ...

2 weeks from now

Oct 7, 2024 · Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late …

morningstar.com

$2
OFF

Scholar Rock Preps Filings After SMA Antibody Clears Trial

2 weeks from now

3 days ago · Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

pharmaphorum.com

$300
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

2 weeks from now

Oct 9, 2024 · The offering includes pre-funded warrants to purchase 353,983 shares at the public offering price. Scholar Rock has also granted underwriters a 30-day option to purchase up to …

medcitynews.com

$345
OFF

Scholar Rock's SMA Drug Hits Phase 3 Trial Goals; Secures $345M …

2 weeks from now

Nov 12, 2024 · Scholar Rock (SRRK) reported positive Phase 3 SAPPHIRE trial results for apitegromab in Spinal Muscular Atrophy (SMA), achieving its primary endpoint with statistically …

stocktitan.net

$36.00
OFF

Scholar Rock Shares Target Increased, Holds Buy On SMA Drug …

2 weeks from now

Nov 25, 2024 · Monday, Truist Securities adjusted its outlook on Scholar Rock (NASDAQ:SRRK) shares, raising the biotechnology company's price target from $36.00 to $45.00 while …

investing.com

$3.82
OFF

Scholar Rock Targets SMA Treatment Launch, Expands Trials

2 weeks from now

Jan 8, 2025 · CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company valued at $3.82 billion, is progressing towards the commercialization of apitegromab, …

investing.com

$3.82
OFF

Scholar Rock Targets SMA Treatment Launch, Expands Trials

2 weeks from now

Jan 8, 2025 · CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company valued at $3.82 billion, is progressing towards the commercialization of apitegromab, …

investing.com

FAQs about Scholar Rock stocks skyrocket after SMA drug scores at Phase III Coupon?

Will scholar rock get regulatory approval after positive SMA results?

Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. ...

Is scholar rock a key target for spinal muscular atrophy (SMA)?

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite the higher dose falling short of the targeted efficacy and Scholar Rock making no mention of a key secondary goal. ...

Should you buy scholar rock holding (SRRK) stock?

Scholar Rock Holding is rated a Strong Buy based on the cumulative recommendations of five analysts. The average price target for SRRK stock is $29.67, representing a potential 0.61% change from current levels. Scholar Rock has recently announced success in a phase 3 trial, sparking a remarkable surge in the company’s share price. ...

Did scholar rock achieve its main target in a late-stage trial?

Scholar Rock's experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading. ...

Does scholar rock's apitegromab improve motor function in SMA patients?

Scholar Rock's apitegromab showed significant motor function improvements in SMA patients, achieving primary endpoints in the Phase 3 SAPPHIRE trial. Apitegromab's unique approach targets precursor myostatin, potentially reducing side effects compared to traditional myostatin inhibitors. ...

Is scholar rock a good SMA drug?

Additionally, 30% of those on Scholar Rock’s drug had at least a three-point improvement on a ratings scale widely used to evaluate SMA therapies. By comparison, 12.5% of placebo recipients hit that mark. ...